Skip to main content

Advertisement

SpringerLink
Log in

Bone-targeting agents in prostate cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502–1512.

    Article  CAS  PubMed  Google Scholar 

  2. Kantoff, P. W., Higano, C. S., Shore, N. D., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411–422.

    Article  CAS  PubMed  Google Scholar 

  3. de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet, 376(9747), 1147–1154.

    Article  Google Scholar 

  4. Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369(3), 213–223.

    Article  CAS  PubMed  Google Scholar 

  5. Fizazi, K., Scher, H. I., Molina, A., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 13, 983–992.

    Article  CAS  PubMed  Google Scholar 

  6. Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. Journal of Clinical Oncology, 30(Suppl 5), 1.

    Google Scholar 

  7. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet, 133(3421), 571–573.

    Article  Google Scholar 

  8. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Reviews, 20(3), 345–357.

    Article  CAS  PubMed  Google Scholar 

  9. Wada, T., Nakashima, T., Hiroshi, N., & Penninger, J. M. (2006). RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends in Molecular Medicine, 12(1), 17–25.

    Article  CAS  PubMed  Google Scholar 

  10. Shiozawa, Y., Pedersen, E. A., Havens, A. M., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Pedersen, E. A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2012). The prostate cancer bone marrow niche: more than just ‘fertile soil’. Asian Journal of Andrology, 14(3), 423–427.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Schneider, A., Kalikin, L. M., Mattos, A. C., et al. (2005). Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology, 146(4), 1727–1736.

    Article  CAS  PubMed  Google Scholar 

  13. Shiozawa, Y., Pedersen, E. A., Patel, L. R., et al. (2010). GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, NY), 12(2), 116.

    CAS  Google Scholar 

  14. Taichman, R. S., Patel, L. R., Bedenis, R., et al. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PloS one, 8(4), e61873.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Loberg, R. D., Gayed, B. A., Olson, K. B., & Pienta, K. J. (2005). A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions. Journal of Cellular Biochemistry, 96(3), 439–446.

    Article  CAS  PubMed  Google Scholar 

  16. Guise, T. A., Mohammad, K. S., Clines, G., et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical cancer research, 12(20), 6213s–6216s.

    Article  CAS  PubMed  Google Scholar 

  17. Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O. (2003). Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology, 21(23), 4277–4284.

    Article  CAS  PubMed  Google Scholar 

  18. Saad, F., Gleason, D. M., Murray, R., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879–882.

    Article  CAS  PubMed  Google Scholar 

  19. Rosen, L. S., Gordon, D., Kaminski, M., et al. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98(8), 1735–1744.

    Article  CAS  PubMed  Google Scholar 

  20. Smith, M. R., Halabi, S., Ryan, C. J., et al. (2013). Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). ASCO Meeting Abstracts, 31(6_suppl), 27.

    Google Scholar 

  21. Wirth, M., Tammela, T., Huland, H., et al. (2008). Zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients. A randomised, open label, multicentre study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). European Urology Supplements, 7(3), 232.

    Article  Google Scholar 

  22. Smith, M. R., Egerdie, B., Toriz, N. H., et al. (2009). Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine, 361(8), 745–755.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Fizazi, K., Lipton, A., Mariette, X., et al. (2009). Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology, 27(10), 1564–1571.

    Article  CAS  PubMed  Google Scholar 

  24. Fizazi, K., Carducci, M., Smith, M., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet, 377(9768), 813–822.

    Article  CAS  Google Scholar 

  25. Smith, M. R., Saad, F., Coleman, R., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet, 379(9810), 39–46.

    Article  CAS  Google Scholar 

  26. Summary minutes of the Oncologic Drugs Advisory Committee meeting. 2012.

  27. Silberstein, E. B. (1996). Dosage and response in radiopharmaceutical therapy of painful osseous metastases. Journal of Nuclear Medicine, 37(2), 249–252.

    CAS  PubMed  Google Scholar 

  28. Tu, S., Millikan, R. E., Mengistu, B., et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. The Lancet, 357(9253), 336–341.

    Article  CAS  Google Scholar 

  29. Sartor, O., Reid, R. H., Bushnell, D. L., Quick, D. P., & Ell, P. J. (2007). Safety and efficacy of repeat administration of samarium Sm–153 lexidronam to patients with metastatic bone pain. Cancer, 109(3), 637–643.

    Article  CAS  PubMed  Google Scholar 

  30. Fizazi, K., Beuzeboc, P., Lumbroso, J., et al. (2009). Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology, 27(15), 2429–2435.

    Article  CAS  PubMed  Google Scholar 

  31. James, N. D., Pirrie, S., Barton, D., et al. (2013). Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). ASCO Meeting Abstracts, 31(18_suppl), LBA5000.

    Google Scholar 

  32. Nilsson, S., Franzén, L., Parker, C., et al. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology, 8(7), 587–594.

    Article  CAS  PubMed  Google Scholar 

  33. Nilsson, S., Strang, P., Aksnes, A. K., et al. (2012). A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer, 48(5), 678–686.

    Article  CAS  PubMed  Google Scholar 

  34. Morris, M. J., Hammers, H. J., Sweeney, C., et al. (2013). Safety of radium-223 dichloride (ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate cancer clinical trials consortium study. ASCO Meeting Abstracts, 31(15_suppl), 5021.

    Google Scholar 

  35. Carducci, M. A., Padley, R. J., Breul, J., et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Journal of Clinical Oncology, 21(4), 679–689.

    Article  CAS  PubMed  Google Scholar 

  36. Schelman, W. R., Liu, G., Wilding, G., Morris, T., Phung, D., & Dreicer, R. (2011). A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs, 29(1), 118–125.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. James, N. D., Caty, A., Payne, H., et al. (2010). Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration–resistant prostate cancer and bone metastases who were pain–free or mildly symptomatic for pain: a double–blind, placebo–controlled, randomized phase II trial. BJU International, 106(7), 966–973.

    Article  CAS  PubMed  Google Scholar 

  38. Nelson, J. B., Love, W., Chin, J. L., et al. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone–refractory prostate cancer. Cancer, 113(9), 2478–2487.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo–controlled study of zibotentan (ZD4054) in patients with castration–resistant prostate cancer metastatic to bone. Cancer, 118(22), 5709–5718.

    Article  CAS  PubMed  Google Scholar 

  40. Miller, K., Moul, J., Gleave, M., et al. (2013). Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 16(2), 187–192.

    Article  CAS  PubMed  Google Scholar 

  41. Akhavan, A., McHugh, K. H., Guruli, G., et al. (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia, 8(9), 725–732.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Kim, L. C., Song, L., & Haura, E. B. (2009). Src kinases as therapeutic targets for cancer. Nature Reviews Clinical Oncology, 6(10), 587–595.

    Article  PubMed  Google Scholar 

  43. Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer and Metastasis Reviews, 22(4), 337–358.

    Article  CAS  PubMed  Google Scholar 

  44. Edwards, J. (2010). Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), 605–614.

    Article  CAS  PubMed  Google Scholar 

  45. Tatarov, O., Mitchell, T. J., Seywright, M., Leung, H. Y., Brunton, V. G., & Edwards, J. (2009). SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clinical Cancer Research, 15(10), 3540–3549.

    Article  CAS  PubMed  Google Scholar 

  46. Nam, S., Kim, D., Cheng, J. Q., et al. (2005). Action of the src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research, 65(20), 9185–9189.

    Article  CAS  PubMed  Google Scholar 

  47. Brownlow, N., Mol, C., Hayford, C., Ghaem-Maghami, S., & Dibb, N. (2008). Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia, 23(3), 590–594.

    Article  PubMed  Google Scholar 

  48. Lee, Y., Huang, C., Murshed, M., Chu, K., Araujo, J. C., & Ye, X. (2010). Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene, 29(22), 3196–3207.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., et al. (2013). Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol, 14(13), 1307–1316.

    Google Scholar 

  50. Araujo, J. C., Mathew, P., Armstrong, A. J., et al. (2012). Dasatinib combined with docetaxel for castration–resistant prostate cancer. Cancer, 118(1), 63–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Anderson, G., Gries, M., Kurihara, N., et al. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 107(8), 3098–3105.

    Article  CAS  PubMed  Google Scholar 

  52. Efstathiou, E., Troncoso, P., Wen, S., et al. (2007). Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clinical Cancer Research, 13(4), 1224–1231.

    Article  CAS  PubMed  Google Scholar 

  53. Vallet, S., Palumbo, A., Raje, N., et al. (2008). Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma, 49(7), 1238–1245.

    Article  CAS  PubMed  Google Scholar 

  54. Dahut, W. L., Gulley, J. L., Arlen, P. M., et al. (2004). Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology, 22(13), 2532–2539.

    Article  CAS  PubMed  Google Scholar 

  55. Petrylak D, Fizazi K, Sternberg C, Budnik N, Wit Rd WP. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial. 2012.

  56. Chott, A., Sun, Z., Morganstern, D., et al. (1999). Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. The American Journal of Pathology, 155(4), 1271–1279.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Sulpice, E., Ding, S., Muscatelli-Groux, B., et al. (2009). Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biology of the Cell, 101(9), 525–539.

    Article  CAS  PubMed  Google Scholar 

  58. Tsai, S., Huang, Y., Yang, W., & Tang, C. (2012). Hepatocyte growth factor-induced BMP-2 expression is mediated by c-met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts. International Immunopharmacology, 13(2), 156–162.

    Article  CAS  PubMed  Google Scholar 

  59. Ryan, C. J., Rosenthal, M., Ng, S., et al. (2013). Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clinical Cancer Research, 19(1), 215–224.

    Article  CAS  PubMed  Google Scholar 

  60. Kelly, W. K., Halabi, S., Carducci, M., et al. (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology, 30(13), 1534–1540.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Smith, D. C., Smith, M. R., Sweeney, C., et al. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412–419.

    Article  CAS  PubMed  Google Scholar 

  62. Isaacs, J. T., Pili, R., Qian, D. Z., et al. (2006). Identification of ABR–215050 as lead second generation quinoline–3–carboxamide anti–angiogenic agent for the treatment of prostate cancer. Prostate, 66(16), 1768–1778.

    Article  CAS  PubMed  Google Scholar 

  63. Isaacs, J. T. (2010). The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 19(10), 1235–1243.

    Article  CAS  PubMed  Google Scholar 

  64. Olsson, A., Björk, A., Vallon-Christersson, J., Isaacs, J. T., & Leanderson, T. (2010). Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer, 9(1), 107.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Isaacs, J. T., Antony, L., Dalrymple, S. L., et al. (2013). Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research, 73(4), 1386–1399.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Jennbacken, K., Welén, K., Olsson, A., et al. (2012). Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline–3–carboxamide tasquinimod (ABR–215050). Prostate, 72(8), 913–924.

    Article  CAS  PubMed  Google Scholar 

  67. Bratt, O., Häggman, M., Ahlgren, G., Nordle, Ö., Björk, A., & Damber, J. (2009). Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer, 101(8), 1233–1240.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Pili, R., Häggman, M., Stadler, W. M., et al. (2011). Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 29(30), 4022–4028.

    Article  CAS  PubMed  Google Scholar 

  69. Armstrong, A. J., Haggman, M., Stadler, W. M., et al. (2012). Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology, 30(15 Suppl), 4550.

    Google Scholar 

  70. Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  71. Ryan, C. J., Smith, M. R., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138–148.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Logothetis, C. J., Basch, E., Molina, A., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The lancet oncology., 13, 1210–7.

    Article  CAS  PubMed  Google Scholar 

  73. Tran, C., Ouk, S., Clegg, N. J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787–790.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Fizazi, K., Scher, H., Saad, F., et al. (2012). Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Annals of Oncology, 23, 295–296.

    Article  Google Scholar 

  75. Jensen, A. B., Wynne, C., Ramirez, G., et al. (2010). The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical Breast Cancer, 10(6), 452–458.

    Article  CAS  PubMed  Google Scholar 

  76. Taichman, R. S. (2005). Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood, 105(7), 2631–2639.

    Article  CAS  PubMed  Google Scholar 

  77. Joyce, J. A., & Pollard, J. W. (2008). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1 M45, Baltimore, MD, 21231-1000, USA

    Daniel L. Suzman, Sosipatros A. Boikos & Michael A. Carducci

Authors
  1. Daniel L. Suzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sosipatros A. Boikos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. Carducci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Carducci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzman, D.L., Boikos, S.A. & Carducci, M.A. Bone-targeting agents in prostate cancer. Cancer Metastasis Rev 33, 619–628 (2014). https://doi.org/10.1007/s10555-013-9480-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-013-9480-2

Keyword

Search

Navigation